Area Vice President of Sales - Tech Partnerships

Komodo expands strategic partnership with Alnylam to scale ai-powered intelligence platform. Expanded agreement extends Marmot across key enterprise functions, advancing a new operating model for AI-powered decision-making in Life Sciences. Komodo also unveils new Marmot capabilities to move organizations beyond AI experimentation and into enterprise-wide intelligence. NEW YORK, SAN FRANCISCO - June 25, 2026 - Komodo Health(R), the leader in AI-powered healthcare intelligence, today announced an expanded strategic partnership with Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi therapeutics company to scale Marmot(TM), Komodo's analytics AI platform, across key enterprise functions at Alnylam. Built on the Healthcare Map(R), the industry's most comprehensive view of more than 330 million de-identified patient journeys, Marmot helps organizations move beyond fragmented analytics and static reporting toward real-time, transparent, and reproducible healthcare intelligence. Launched in August 2025, Alnylam was an early adopter of the platform, with the collaboration initially focused on building custom AI agents for Alnylam's commercial business function. The expanded partnership will enable Alnylam to deploy Marmot across its customer-facing organization and leverage its capabilities more broadly across the enterprise, creating a unified foundation for data-driven decision-making at scale. "Alnylam's ability to create meaningful impact is built on breakthrough science, strong execution, and an unwavering commitment to patients," said Tolga Tanguler, Chief Commercial Officer at Alnylam. "This new capability strengthens our ability to connect insight into action, helping us scale more effectively, accelerate decision-making, and continue delivering sustainable growth while maintaining our focus on patients." Since initially deploying Marmot, Alnylam and Komodo have built and deployed custom AI agents across critical workflows. Alnylam has integrated a wide range of enterprise datasets into the platform, transforming how teams access and act on insights by eliminating reliance on fragmented dashboards, reducing reporting cycles from months to hours, and enabling teams to generate insights that were previously out of reach. Marmot will continue to support Alnylam as the company works toward a range of operational and patient impact objectives. Advancing the Next Generation of Enterprise Healthcare AI The expanded partnership reflects a broader shift occurring across healthcare and Life Sciences as organizations move beyond AI experimentation and begin adopting new operating models built around real-time intelligence. As the limitations of disconnected dashboards, static reporting, and siloed analytics become increasingly apparent, the focus is turning toward enterprise-wide systems that can continuously generate, distribute, and operationalize trusted, verifiable insights across teams. "We're moving from a world where every team operates from its own reports and analyses to one where an entire enterprise sees the same reality in real time and can act on it," said Arif Nathoo, MD, CEO and Co-Founder of Komodo Health. "Marmot is not only a productivity improvement; it's a new operating model. Alnylam is demonstrating what becomes possible when AI evolves into an intelligence layer that powers how an organization runs." New Marmot Capabilities Support Enterprise-Wide Adoption To support this next phase of enterprise AI adoption, Komodo also released several new Marmot capabilities designed to make healthcare intelligence accessible to every user, from business leaders and consultants to analysts and data scientists. These latest capabilities deliver unprecedented visibility, knowledge, and control over healthcare data, ensuring every analysis is reproducible, verifiable, and executed with unmatched speed and confidence. "The organizations seeing the greatest value from AI aren't simply generating insights faster; they're embedding trusted intelligence directly into the workflows that drive critical decisions," said Amit Sangani, Chief Technology Officer at Komodo. "These new capabilities are designed to help organizations move beyond experimentation and build AI into the core processes that drive the enterprise, without sacrificing the scientific rigor healthcare demands." About Komodo Health Komodo Health(R) is building the trusted AI-powered intelligence layer for healthcare and Life Sciences. Powered by the Healthcare Map(R), the industry's most comprehensive view of more than 330 million de-identified patient journeys, Komodo's healthcare-native AI analytics platform, Marmot(TM), equips organizations with the intelligence needed to answer critical healthcare questions across clinical development, market access, commercialization, and real-world evidence. Designed for transparency, auditability, and reproducibility, Marmot enables teams to move from question to decision with greater speed and confidence. * Related Topics: Press Releases

Komodo Health names Miles Ennis President in Executive leadership shift. June 16, 2026 Miles Ennis Komodo Health has named Miles Ennis President and elevated co-founder Web Sun to co-Chief Executive Officer, updating its leadership structure as the healthcare intelligence company looks to scale adoption of its AI platform across healthcare and life sciences organizations. Sun will serve as co-CEO alongside co-founder and CEO Arif Nathoo, M.D., while Ennis will take on expanded responsibility for commercial execution, operations, product strategy alignment and marketing. The company said the changes are intended to support its next phase of growth as customers move from artificial intelligence pilots toward broader enterprise deployment. Komodo's platform strategy centers on Marmot, its healthcare-native AI analytics platform, which is designed to help organizations generate verifiable and reproducible evidence from healthcare data. The company positions Marmot as an enterprise intelligence layer for life sciences and healthcare teams seeking faster answers to complex questions across clinical development, market access, commercialization and real-world evidence. "The next era of healthcare AI will be defined by vertical AI platforms that combine deep domain expertise, trusted data foundations, and purpose-built intelligence, and we believe Komodo is positioned to lead that category," Nathoo said. "We have tremendous confidence in the opportunity ahead and are committed to continuing to invest in our platform, our people, and our partners to meet the growing demand for healthcare-native AI." Ennis joined Komodo as Chief Revenue Officer in July 2024 and was named Chief Operating Officer in September 2025. Since joining the company, he has helped drive commercialization of Marmot and expand strategic relationships across Komodo's partner ecosystem. As President, Ennis will focus on scaling the company's go-to-market organization and strengthening operational execution as demand grows for AI tools built specifically for healthcare and life sciences workflows. His responsibilities will include aligning product innovation with customer needs and helping ensure the platform delivers measurable value across enterprise deployments. "Healthcare and Life Sciences organizations are moving beyond AI pilots and looking for solutions that work at enterprise scale, built on data they can trust and a platform designed for the complexity of healthcare," Ennis said. "That is exactly what Komodo delivers, and as President, my focus will be to ensure our platform delivers measurable value and impact for the organizations we serve." The leadership shift comes as healthcare companies, pharmaceutical manufacturers and life sciences organizations increasingly seek AI systems that can operate within highly regulated, data-intensive environments. For those customers, the ability to produce transparent, auditable and reproducible outputs is becoming central to enterprise adoption. Komodo's Healthcare Map includes more than 330 million de-identified patient journeys, providing the data foundation for its analytics and AI tools. The company said Marmot is designed to help teams move from business or clinical questions to decisions more quickly while maintaining transparency and auditability. Sun said the updated leadership model reflects both the scale of the company's opportunity and the complexity of its next growth phase. "This evolved leadership structure reflects the scale of the opportunity ahead and the operating complexity of this next phase of growth," Sun said. "Miles has consistently demonstrated the ability to connect strategy, product innovation, customer needs, and execution, a capability that becomes even more important as AI reshapes what is possible in healthcare and Life Sciences." Komodo Health provides AI-powered healthcare intelligence for organizations working across clinical development, market access, commercialization and real-world evidence. Through its Healthcare Map and Marmot platform, the company aims to support faster, more reliable decision-making in healthcare and life sciences markets where data quality, workflow integration and evidence generation are critical to scaling AI use.

Komodo Health appoints Paul Thomas as Chief Financial Officer. Finance veteran to oversee financial strategy as demand for company's AI platform accelerates. NEW YORK & SAN FRANCISCO - April 30, 2026 - Komodo Health, the leader in AI-powered healthcare intelligence, today announced the promotion of Paul Thomas to Chief Financial Officer (CFO). In this role, Thomas, who has served as Senior Vice President of Finance and Acting CFO since April 2025, will oversee Komodo's finance organization and enterprise financial strategy. The appointment comes as the industry reaches an inflection point, with organizations moving beyond using AI as a productivity layer to building and operationalizing it as a core enterprise capability. Komodo is leading this shift with Marmot(TM), its AI analytics platform built on the Healthcare Map(R), the industry's most comprehensive view of 330+ million patient journeys. Marmot enables organizations to move from static reporting and delayed insights to real-time, trusted intelligence and accelerate critical decision-making across the product life cycle, from trial design to launch strategy to post-market evidence generation. As adoption of Marmot increases across healthcare and Life Sciences organizations, the ability to align capital allocation, investment strategy, and long-term platform development is essential to sustaining growth. "Paul's expertise has been instrumental in advancing Komodo's strong financial foundation and positioning us for our next phase of AI-led growth," said Web Sun, President and Co-Founder, Komodo Health. "As our customers move from treating AI as a productivity tool to embedding it as a core part of how they operate, the discipline and strategic alignment he brings will be essential as we continue to scale." Since joining Komodo Health, Thomas has played a central role in strengthening the company's financial strategy, improving operational rigor and enabling disciplined investment across product innovation and go-to-market expansion. His leadership has helped ensure that Komodo can scale aggressively while continuing to invest in the infrastructure required to support enterprise-grade AI development and deployment. "Komodo is building the AI-powered intelligence that is fundamentally changing how organizations make decisions," said Thomas. "My focus is on ensuring we have the financial strategy, systems, and discipline to support that growth while continuing to invest in the platform and capabilities that drive impact for our customers." Thomas brings more than 20 years of experience in private and public company finance, strategic planning, and investment research. Prior to Komodo Health, he led Strategic Finance and Investor Relations at Talkdesk and played a key role in taking Sumo Logic public in 2020. He began his career as a semiconductor engineer at Intel Corporation before moving into finance roles at Merrill Lynch, Bank of America, and Goldman Sachs. About Komodo Health Komodo Health is on a mission to reduce the global burden of disease by building foundational AI for how Life Sciences and healthcare organizations discover, develop, and deliver life-saving therapies. The company's healthcare-native AI platform Marmot, powered by its Healthcare Map, eliminates slow, fragmented analyses to accelerate critical healthcare decisions across the product life cycle - from trial design to launch strategy to post-market evidence generation. For more information, visit www.komodohealth.com.